IMGNライブシグナル | Getagraph.comで利益を最大化

売る 116555 min ago

@ $31.23

発行日: 8 2月 2024 @ 23:30

リターン: 0.02%

前回のシグナル: 2月 8 - 05:55

前回のシグナル: 買う

リターン: 5.67 %

Live Chart Being Loaded With Signals

Commentary (10 2月 2024 @ 05:58):

Stats
本日の出来高	19.31M
平均出来高	8.29M
時価総額	8.73B
EPS	$0 ( 2024-04-26 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-111.55
ATR14	$0.306 (0.98%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-12	Mitchell Dean J	Sell	103 000	Common Stock
2024-02-12	Mitchell Dean J	Sell	13 090	Restricted Stock Unit
2024-02-12	Mitchell Dean J	Sell	142 667	Deferred Share Unit
2024-02-12	Mitchell Dean J	Sell	10 000	Stock Option (Right to Buy)
2024-02-12	Mitchell Dean J	Sell	10 000	Stock Option (Right to Buy)

INSIDER POWER
-100.00
Last 100 transactions
Buy: 0 \| Sell: 8 781 240

ボリューム相関

長: 0.24 (neutral)

短: 0.25 (neutral)

Signal:(82.516) Neutral

ImmunoGen Inc 相関

10 最も正の相関
HOL	0.945
IRBT	0.93
SLNG	0.929
RTPY	0.927
KBSF	0.926
LGMK	0.92
RPID	0.919
FIBK	0.917
GBCI	0.917
LYEL	0.917

10 最も負の相関
AEAE	-0.941
ENTF	-0.941
CCTS	-0.941
HORI	-0.939
GHIX	-0.938
FIAC	-0.938
XPAX	-0.938
NECB	-0.936
ADAL	-0.935
ACAB	-0.935

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

ImmunoGen Inc 相関 - 通貨/商品

-0.22
( neutral )

0.51
( weak )

0.55
( weak )

-0.04
( neutral )

0.06
( neutral )

0.26
( neutral )

ImmunoGen Inc 財務諸表

Annual	2022
収益:	$108.78M
総利益:	$108.61M (99.84 %)
EPS:	$-0.880

FY	2022
収益:	$108.78M
総利益:	$108.61M (99.84 %)
EPS:	$-0.880

FY	2022
収益:	$108.78M
総利益:	$108.61M (99.84 %)
EPS:	$-0.880

FY	2020
収益:	$132.30M
総利益:	$17.71M (13.38 %)
EPS:	$-0.250

Financial Reports:

No articles found.

ImmunoGen Inc

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.